Get all your news in one place.
100's of premium titles.
One app.
Start reading
Euronews
Euronews
AP with Doloresz Katanich

Pfizer eyes obesity drug market as it seals $4.9bn deal for Metsera

US pharmaceutical company Pfizer is hoping to push its way into the obesity drug market by acquiring biopharmaceutical firm Metsera for $4.9 billion (€4.16bn).

The deal brings Metsera's pipeline of therapies for obesity and cardiometabolic diseases, along with its expertise and infrastructure, into Pfizer's portfolio.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.